OIP5-AS1

Summary

OIP5-AS1 (OIP5 antisense RNA 1, HGNC:43563) is a long non-coding RNA gene on chromosome 15q15.1.

This is a conserved gene that produces a long non-coding RNA that maintains cell proliferation in embryonic stem cells. This RNA can bind to and negatively regulate the activity of multiple cellular RNAs and microRNAs, including cyclin G associated kinase and ELAV like RNA binding protein 1.

Source: NCBI Gene 729082 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43563
Approved symbol	OIP5-AS1
Name	OIP5 antisense RNA 1
Location	15q15.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	cyrano, linc-OIP5
Ensembl gene	ENSG00000247556
Ensembl biotype	lncRNA
Entrez	729082
RNAcentral	URS0000CCE04C — lncRNA, 8844 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 73 — 73 lncRNA

ENST00000500949, ENST00000501665, ENST00000557993, ENST00000558457, ENST00000558945, ENST00000559368, ENST00000560545, ENST00000560706, ENST00000561226, ENST00000561275, ENST00000706990, ENST00000706991, ENST00000706992, ENST00000706993, ENST00000707002, ENST00000707003, ENST00000707004, ENST00000707005, ENST00000707006, ENST00000707007, ENST00000707008, ENST00000707009, ENST00000707010, ENST00000707011, ENST00000707012, ENST00000707013, ENST00000707014, ENST00000707015, ENST00000707016, ENST00000707017, ENST00000707018, ENST00000707019, ENST00000707020, ENST00000707021, ENST00000707022, ENST00000707023, ENST00000707024, ENST00000707025, ENST00000707026, ENST00000707027, ENST00000707028, ENST00000707029, ENST00000707030, ENST00000707031, ENST00000707032, ENST00000707034, ENST00000707035, ENST00000707036, ENST00000707037, ENST00000707038, ENST00000707039, ENST00000707040, ENST00000707041, ENST00000707042, ENST00000707043, ENST00000707044, ENST00000707045, ENST00000707046, ENST00000707047, ENST00000707048, ENST00000707049, ENST00000707050, ENST00000707051, ENST00000707052, ENST00000707053, ENST00000707054, ENST00000707055, ENST00000707056, ENST00000707057, ENST00000707058, ENST00000707059, ENST00000707061, ENST00000821975

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000500949 — 4 exons

Exon	Start	End
ENSE00001964306	41283958	41284110
ENSE00001967414	41298041	41306539
ENSE00001974199	41286011	41286100
ENSE00002554569	41285225	41285363

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.0831 / max 665.5124, expressed in 1812 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146173	32.5948	1812
146172	1.4882	723

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	99.59	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.57	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.56	gold quality
middle temporal gyrus	UBERON:0002771	99.51	gold quality
postcentral gyrus	UBERON:0002581	99.48	gold quality
endothelial cell	CL:0000115	99.46	gold quality
left ventricle myocardium	UBERON:0006566	99.32	gold quality
parietal lobe	UBERON:0001872	99.27	gold quality
ileal mucosa	UBERON:0000331	99.21	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.21	gold quality
tibialis anterior	UBERON:0001385	99.10	gold quality
deltoid	UBERON:0001476	99.09	gold quality
pons	UBERON:0000988	99.03	gold quality
entorhinal cortex	UBERON:0002728	98.96	gold quality
lateral globus pallidus	UBERON:0002476	98.94	gold quality
superior frontal gyrus	UBERON:0002661	98.92	gold quality
upper arm skin	UBERON:0004263	98.85	gold quality
upper leg skin	UBERON:0004262	98.81	gold quality
vastus lateralis	UBERON:0001379	98.75	gold quality
biceps brachii	UBERON:0001507	98.66	gold quality
myocardium	UBERON:0002349	98.61	gold quality
occipital lobe	UBERON:0002021	98.51	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.49	gold quality
kidney epithelium	UBERON:0004819	98.45	gold quality
primary visual cortex	UBERON:0002436	98.37	gold quality
substantia nigra pars compacta	UBERON:0001965	98.07	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.05	gold quality
dorsal plus ventral thalamus	UBERON:0001897	98.04	gold quality
quadriceps femoris	UBERON:0001377	98.03	gold quality
skin of hip	UBERON:0001554	97.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.65

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-424 interacts with long non-coding RNA OIP5-AS1 and competes with HuR for binding to OIP5-AS1. (PMID:26819413)
• Quantitative real-time polymerase chain reaction to determine the expression of linc-OIP5 in glioma tissues and in adjacent normal tissues. Level of linc-OIP5 was up-regulated in glioma tissues and significantly correlated with the advanced tumor stage (III/IV). (PMID:28189759)
• These findings indicate that the abnormal mitoses seen after silencing OIP5-AS1 were caused by an untimely rise in GAK levels and suggest that OIP5-AS1 suppresses cell proliferation at least in part by reducing GAK levels. (PMID:28472763)
• OIP5-AS1 positively regulates cell proliferation by promoting G2/M phase progression. (PMID:29277759)
• PIWIL3 was also a target of CEBPA, forming a positive feedback loop in the growth regulation of glioma cells. Significantly, knockdown of OIP5-AS1 combined with over-expression of PIWIL3 and miR-367-3p resulted in tumor regression and extended survival in vivo. (PMID:29464001)
• OIP5-AS1 overexpression in undifferentiated oral tumors may be suggestive of enhanced cancer stemness, and consequently, poor clinical outcome. (PMID:29728583)
• Study found that OIP5-AS1 was highly expressed in lung cancer tissues and was correlated with tumor size and growth speed. Its overexpression increased lung cancer cell proliferation in vitro. LncRNA OIP5-AS1 seemed to promote lung cancer cell proliferation by competitively binding miR-378a. (PMID:29897167)
• OIP5-AS1 acts as a miR-223 ‘sponge’ to trigger CDK14 expression to promote osteosarcoma tumorigenesis. (PMID:30119217)
• OIP5-AS1 promoted proliferation and invasion of cervical cancer cells via increasing the ITGA6 expression by sponging miR-143-3p, which might be an effective therapeutic target for the treatment of patients with cervical cancer. (PMID:30188591)
• LncRNA OIP5-AS1 promoted SMAD3 expression via mediating miR-143-3p to promote migration and invasion of cervical cancer cells. (PMID:30341904)
• Long non-coding RNA Opa interacting protein 5-antisense RNA 1 (OIP5-AS1) downregulation targets sex-determining region Y-box 2 (SOX2) by miR-129-5p upregulation. (PMID:30443959)
• OIP5-AS1 is possibly a novel biomarker of NSCLC in Iranian patients (PMID:30541307)
• OIP5-AS1 could relieve osteogenic differentiation of valve interstitial cells via upregulating miR-137 target gene TWIST1. (PMID:30846207)
• Long noncoding RNA OIP5-AS1 aggravates cell proliferation, migration in gastric cancer by epigenetically silencing NLRP6 expression via binding EZH2. (PMID:31219209)
• review our current understanding of OIP5-AS1 in carcinogenesis and its potential application as a clinical biomarker or therapeutic target in malignancy (PMID:31476304)
• Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641. (PMID:31858545)
• Prognostic and clinicopathologic significance of long non-coding RNA opa-interacting protein 5-antisense RNA 1 in multiple human cancers. (PMID:31899963)
• Long non-coding RNA OIP5-AS1 serves as an oncogene in laryngeal squamous cell carcinoma by regulating miR-204-5p/ZEB1 axis. (PMID:32009213)
• Downregulation of LncRNA OIP5-AS1 Induced by IL-1beta Aggravates Osteoarthritis via Regulating miR-29b-3p/PGRN. (PMID:32037864)
• LncRNA OIP5-AS1 interacts with miR-363-3p to contribute to hepatocellular carcinoma progression through up-regulation of SOX4. (PMID:32042127)
• LNCRNA OIP5-AS1 regulates oxidative low-density lipoprotein-mediated endothelial cell injury via miR-320a/LOX1 axis. (PMID:32072428)
• LncRNA OIP5-AS1 facilitates gastric cancer cell growth by targeting the miR-422a/ANO1 axis. (PMID:32147682)
• Long non-coding RNA OIP5-AS1 promotes pancreatic cancer cell growth through sponging miR-342-3p via AKT/ERK signaling pathway. (PMID:32157498)
• LncRNA OIP5-AS1 promotes cell proliferation and migration and induces angiogenesis via regulating miR-3163/VEGFA in hepatocellular carcinoma. (PMID:32329664)
• Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma. (PMID:32460190)
• LncRNA OIP5-AS1 induces epithelial-to-mesenchymal transition and renal fibrosis in diabetic nephropathy via binding to miR-30c-5p. (PMID:32519534)
• The Long Non-coding RNA Cyrano Is Dispensable for Pluripotency of Murine and Human Pluripotent Stem Cells. (PMID:32531193)
• Long non-coding RNA OIP5-AS1 plays an oncogenic role in ovarian cancer through targeting miR-324-3p/NFIB axis. (PMID:32706064)
• LncRNA OIP5-AS1 Promotes Breast Cancer Progression by Regulating miR-216a-5p/GLO1. (PMID:32916503)
• Long non coding RNA OIP5AS1 promotes metastasis of breast cancer via miR3405p/ZEB2 axis. (PMID:32945479)
• Long Noncoding RNA OIP5-AS1 Inhibits Cell Apoptosis and Cataract Formation by Blocking POLG Expression Under Oxidative Stress. (PMID:33006594)
• LncRNA OIP5-AS1 upregulates snail expression by sponging miR-34a to promote ovarian carcinoma cell invasion and migration. (PMID:33092644)
• LncRNA OIP5AS1 aggravates house dust miteinduced inflammatory responses in human bronchial epithelial cells via the miR1433p/HMGB1 axis. (PMID:33174035)
• Interaction of OIP5-AS1 with MEF2C mRNA promotes myogenic gene expression. (PMID:33270893)
• Up-regulating lncRNA OIP5-AS1 protects neuron injury against cerebral hypoxia-ischemia induced inflammation and oxidative stress in microglia/macrophage through activating CTRP3 via sponging miR-186-5p. (PMID:33516048)
• Long Noncoding RNA OIP5-AS1 Promotes the Disease Progression in Nasopharyngeal Carcinoma by Targeting miR-203. (PMID:33628831)
• Long noncoding RNA OIP5AS1 facilitates the progression of ovarian cancer via the miR1283p/CCNG1 axis. (PMID:33760168)
• OPA Interacting Protein 5 Antisense RNA 1 Expedites Cell Migration and Invasion Through FOXM1/ Wnt/beta-Catenin Pathway in Pancreatic Cancer. (PMID:33782807)
• Long noncoding RNA OIP5-AS1 exhibits oncogenic activity in bladder cancer through miR-217 and MTDH. (PMID:33928606)
• Molecular mechanism of miR-34b-5p and RNA binding protein HuR binding to lncRNA OIP5-AS1 in colon cancer cells. (PMID:34021273)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.